We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00800852
First Posted: December 2, 2008
Last Update Posted: December 2, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Samsung Medical Center
November 30, 2008
December 2, 2008
December 2, 2008
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome
Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome

The inflammatory process is involved in the pathogenesis of obesity. Prader-Willi syndrome (PWS) is a genetic model of syndromic obesity. Adiponectin is an adipokine with potent anti-inflammatory properties, and its effect is mediated through adiponectin receptors 1 (adipoR1) and 2 (adipoR2).

Objective of this study is to compare the expression of adipoR1, adipoR2, and adiponectin in peripheral blood mononuclear cells (PBMCs) in PWS children and obese control and to correlate receptor expression with insulin sensitivity and obesity-related parameters.

Not Provided
Observational
Not Provided
Not Provided
Not Provided
Probability Sample
Fourteen children with PWS and control subjects
  • Obesity
  • Prader-Willi Syndrome
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • children with Prader-willi syndrome
  • children with simple obesity

Exclusion Criteria:

  • subjects with diabetes mellitus (fasting plasma glucose > 126 mg/dL with a 2-h oral glucose tolerance test value of >200 mg/dl)
Sexes Eligible for Study: All
up to 18 Years   (Child, Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00800852
2008-10-040
Yes
Not Provided
Not Provided
Dong-Kyu Jin, Samsung Medical Center
Samsung Medical Center
Not Provided
Principal Investigator: Don-Kyu Jin, M.D. Samsung Medical Center, Sungkyunkwan Uiversity School of Medicine
Samsung Medical Center
November 2008